Quality of psychopharmacological medication use in nursing home residents

Research in Social and Administrative Pharmacy

Volumn 10, Issue 3, 2014, Pages 494-507

  Simoni Wastila, Linda ^a   Wei, Yu Jung ^a   Luong, Mario ^a   Franey, Christine ^a   Huang, Ting Ying ^a   Rattinger, Gail B ^a,b   Zuckerman, Ilene H ^a   Brandt, Nicole ^a   Lucas, Judith A ^c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c Seton Hall University College of Nursing   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Nursing homes; Psychopharmacological medications; Quality of medication use

Indexed keywords

PSYCHOTROPIC AGENT;

AGED; DRUG UTILIZATION; FEMALE; HEALTH CARE QUALITY; HUMAN; MALE; MEDICARE; NURSING HOME; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MEDICARE; NURSING HOMES; PSYCHOTROPIC DRUGS; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 84900472827     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2013.10.003     Document Type: Article

References (62)

1. Medicare: A Strategy for Quality Assurance 1990, IOM, National Academy Press, Washington, DC.
2. McGlynn E., Asch S., Adams J. The quality of health care delivered to adults in the United States. N Engl J Med 2003, 348:2635-2645.
3. To Err Is Human: Building a Safer Health System 2000, IOM, National Academy Press, Washington, DC.
4. Simoni-Wastila L., Ryder P.T., Qian J., Zuckerman I.H., Shaffer T., Zhao L. Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009, 17:417-427.
5. Huybrechts K.F., Schneeweiss S., Gerhard T., et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 2012, 60(3):420-429.
6. Hughes C.M., Lapane K.L., Mor V. Impact of legislation on nursing home care in the United States: lessons for the United Kingdom. BMJ 1999, 319(7216):1060-1062.
7. Omnibus Budget Reconciliation Act of 1987. Public Law 00-203. Subtitle C. Nursing Home Reform Act. 42 USC 1395i-3(a)-(h)(Medicare); 1396r (a)-(h) (Medicaid) 1987, OBRA-87.
8. Wang P.S., Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353:2335-2341.
9. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc 2005, 294:1934-1943.
10. Kales H.C., Kim H.M., Zivin K., et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012, 169:71-79.
11. Liperoti R., Onder G., Landi F., et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009, 70:1340-1347.
12. Gill S.S., Bronskill S.E., Normand S.L., et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007, 146:775-786.
13. Rochon P.A., Normand S.L., Gomes T., et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med May 26 2008, 168:1090-1096.
14. Public Health Advisory: Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbance April 11 2005, FDA.
15. Aparasu R.R., Chatterjee S., Chen H. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann Pharmacother Apr 2013, 47:464-474.
16. Aparasu R.R., Chatterjee S., Mehta S., Chen H. Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents. Med Care Nov 2012, 50:961-969.
17. Mitka M. CMS seeks to reduce antipsychotic use in nursing home residents with dementia. J Am Med Assoc 2012, 308. 119, 121.
18. CMS. Manual System. Unnecessary Medications Guidance. Pub 100-107: State Operations Provider Certification: Transmittal 22: Tag F329 (Rev 22; Issued 12-115-06; Effective/Implementation:12-18-06) 438.25: Unnecessary Drug. ; Accessed 12.10.09. http://www.cms.hhs.gov/transmittals/downloads/R225OMA.pdf.
19. Kales H., Zivin K., Kim H., et al. Trends in antipsychotic use in dementia 2000-2007. Arch Gen Psychiatry 2011, 68:190-197.
20. Chen Y., Briesacher B., Field T., Tija J., Lau D., Gurwitz J. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Int Med 2010, 170:89-95.
21. Huybrechts K., Schneeweiss S., Gerhard T., et al. Comparative safety of antipsychotic medications in nursing home resident. J Am Geriatr Soc 2012, 60:420-429.
22. Briesacher B.A., Limcangco M.R., Simoni-Wastila L., et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Int Med 2005, 165:1280-1285.
23. Boudreau R.M., Hanlon J.T., Roumani Y.F., et al. Central nervous system medication use and incident mobility limitation in community elders: the health, aging, and body composition study. Pharmacoepidemiol Drug Saf 2009, 18:916-922.
24. Hanlon J.T., Boudreau R.M., Roumani Y.F., et al. Number and dosage of central nervous system medications on recurrent falls in community elders: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2009, 64:492-498.
25. Wright R.M., Roumani Y.F., Boudreau R., et al. Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the health, aging and body composition study. J Am Geriatr Soc 2009, 57:243-250.
26. CMS. Nursing Home Compare. ; Accessed 06.11.12. http://www.medicare.gov/NursingHomeCompare/search.aspx?bhcp=1.
27. Long Term Care Minimum Data Set (MDS) Identifiable Data Files 2012, Warehouse CCCD, Accessed 20.02.12. https://www.cms.gov/IdentifiableDataFiles/10_LongTermCareMinimumDataSetMDS.asp.
28. Nursing Home Quality Initiative 2013, The Center for Medicare and Medicaid Services. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/NHQIQualityMeasures.html.
29. Zuckerman I.H., Sato M., Hsu V.D., Hernandez J.J. Validation of a method for identifying nursing home admissions using administrative claims. BMC Health Serv Res 2007, 7:202.
30. Yun H., Kilgore M.L., Curtis J.R., et al. Identifying types of nursing facility stays using medicare claims data: an algorithm and validation. Health Serv Outcomes Res Methodol 2010, 10:100-110.
31. Koroukian S.M., Xu F., Murray P. Ability of Medicare claims data to identify nursing home patients: a validation study. Med Care 2008, 46(11):1184-1187.
32. Iwashyna T.J. On the detection of nursing home use in Medicare claims. Health Serv Outcomes Res Methodol 2003, 4:187-196.
33. Guthrie B., Clark S., McCowan C. The burden of psychotropic drug prescribing in people with dementia: a population database study. Age Ageing Sep 2010, 39:637-642.
34. Rabins P.V., Blacker D., et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias: 2nd ed. Am J Psychiatry Dec 2007, 164(12 suppl):5-56. APA Work Group on Alzheimer's Disease and other Dementias.
35. APA Work Group on Delirium. American Psychiatric Association Practice Guideline for the Treatment of Patients With Delirium. ; Accessed 23.01.12. http://psychiatryonline.org/content.aspx?bookid=28%26sectionid=1663978.
36. Kamble P., Chen H., Sherer J.T., Aparasu R.R. Use ofantipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging 2009, 26:483-492.
37. Karkare S.U., Bhattacharjee S., Kamble P., Aparasu R. Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriatr Pharmacother 2011, 9:109-119.
38. Wu C.S., Ting T.T., Wang S.C., Chang I.S., Lin K.M. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011, 19:151-159.
39. Hanlon J., Wang X., Castle N., et al. Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents. JAm Geriatr Soc 2011, 59:1412-1420.
40. Burrows A.B., Morris J.N., Simon S.E., Hirdes J.P., Phillips C. Development of a minimum data set-based depression rating scale for use in nursing homes. Age Ageing 2000, 29:165-172.
41. APA Work Group on Bipolar Disorder. American Psychiatric Association Practice Guideline for the Treatment of Patients With Bipolar Disorder: 2nd ed. ; Accessed 23.10.12. http://psychiatryonline.org/content.aspx?bookid=28%26sectionid=1669577.
42. APA Work Group on Major Depressive Disorder. American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder: 3rd ed. ; Accessed 23.01.12. http://psychiatryonline.org/content.aspx?bookid=28%26sectionid=1667485.
43. APA Work Group on Schizophrenia. American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia: 2nd ed. ; Accessed 23.01.12. http://psychiatryonline.org/content.aspx?bookid=28%26sectionid=1665359.
44. Kastenschmidt E.K., Kennedy G.J. Depression and anxiety in late life: diagnostic insights and therapeutic options. Mount Sinai J Med New York Jul-Aug 2011, 78:527-545.
45. Geriatric Lexi-Drugs Online. Lexi-Comp, Inc. Updated Last Updated Date. Accessed 18.01.12.
46. Drugdex. Thomson Healthcare. Updated Last Updated Date. Accessed 06.12.10.
47. Rojas-Fernandez C.H., Miller L.J., Sadowski C.A. Considerations in the treatment of geriatric depression: overview of pharmacotherapeutic and psychotherapeutic treatment interventions. Res Gerontol Nurs 2010, 3:176-186.
48. Tampi R., Williamson D., Muralee S., et al. Behavioral and psychological symptoms of dementia: part II: treatment. Clin Geriatr 2011, 19:31-40.
49. Perlman C., Hirdes J. The aggressive behavior scale: a new scale to measure aggression based on the minimum data set. J Am Geriatr Soc 2008, 56:2298-2303.
50. Morris J., Fries B., Morris S. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci Nov 1999, 54:M546-M553.
51. Morris J.N., Fries B.E., Mehr D.R., et al. MDS cognitive performance scale. J Gerontol Jul 1994, 49:M174-M182.
52. Hartmaier S.L., Sloane P.D., Guess H.A., Koch G.G. The MDS cognition scale: a valid instrument for identifying and staging nursing home residents with dementia using the minimum data set. J Am Geriatr Soc 1994, 42:1173-1179.
53. Hirdes J.P., Frijters D.H., Teare G.F. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc Jan 2003, 51(1):96-100.
54. Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents May 2011, OIG, The Office of the Inspector General for the Department of Health and Human Services, Washington, DC, OEI-07-08-00150.
55. Public Health Advisory: Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances 2005, FDA.
56. Stevenson D.G., Decker S.L., Dwyer L.L., et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry 2010, 18:1078-1092.
57. Kaye H.S., Harrington C., LaPlante M.P. Long-term care: who gets it, who provides it, who pays, and how much?. Health Aff (Millwood) 2010, 29:11-21.
58. Avis N.E., Brambilla D.J., Vass K., McKinlay J.B. The effect of widowhood on health: a prospective analysis from the Massachusetts Women's Health Study. Soc Sci Med 1991, 33(9):1063-1070.
59. Cafferata G.L., Meyers S.M. Pathways to psychotropic drugs. Understanding the basis of gender differences. Med Care 1990, 28:285-300.
60. Saad M., Cassagnol M., Ahmed E. The impact of FDA's warning on the use of antipsychotics in clinical practice: a survey. Consult Pharm 2010, 25:739-744.
61. Desai V.C., Heaton P.C., Kelton C.M. Impact of the Food and Drug Administration's antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings. Alzheimers Dement 2012, 8:453-457.
62. Kamble P., Sherer J., Chen H., Aparasu R. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv (Washington, D.C.) 2010, 61:130-136.